The Developmental Therapeutic Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) conducts development of agents with anticancer activity. The agents arise from the NCI Experimental Therapeutics (NExT) program. In addition, development projects could arise from Development of Clinical Imaging Agents and Enhancers (DCIDE) program, Division of Chemoprevention (DCP) program, Type-1 Diabetes RAID program (T1D-RAID), and NIH Rapid Access to Intervention Development (NIH-RAID) program. The NCI intramural program has also been a source of compounds for development. The contractor provides services, personnel, equipment and facilities to manufacture a variety of the selected bulk compounds in multi-gram and/or kilogram scale. The prepared bulk material is to be used for preclinical toxicity studies, preformulation and clinical trials for the various cancer indications. Technical reports submitted by the contractor may be used to support Investigational New Drug Applications (IND) submitted to the US Food and Drug Administration (FDA). Contracts have been chosen as instruments to accomplish the goals of cancer drug development at the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource and Support Contracts (N02)
Project #
N02CM62216-7-0-1
Application #
8151557
Study Section
Project Start
2006-09-29
Project End
2011-09-28
Budget Start
Budget End
Support Year
Fiscal Year
2010
Total Cost
$1,000,000
Indirect Cost
Name
Ash Stevens, Inc.
Department
Type
DUNS #
City
Riverview
State
MI
Country
United States
Zip Code
48192